Do you think it would be fair to say that among the BP companies, GSK is not the sharpest knife in the drawer?
I'll just say that I think GSK really screwed up the P3 trial design for drisapersen and leave it at that. Disappointing news today for RNA to be sure but perhaps this is a good thing for the longer-term and they can find a better partner. I still plan to hold shares indefinitely.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.